Navigation Links
Hovione's TwinCaps(R) Inhaler in Phase III Clinical Trials for Influenza
Date:4/15/2009

LOURES, Portugal, April 15 /PRNewswire/ -- Hovione is pleased to announce that its licensee Daiichi Sankyo (Tokyo, Japan) has informed that it intends to use Hovione's TwinCaps(R) dry powder inhaler device in the launch of the compound CS-8958, an inhaled long-acting neuraminidase inhibitor active against the influenza virus. Daiichi Sankyo has completed patient enrolment for Phase III clinical trials in Japan and other Asian countries and results are expected to be released mid year, including data to confirm the device switching. TwinCaps(R) was specifically developed by Hovione for the indication and licensed to Daiichi Sankyo and Biota Holdings Ltd (Victoria, Australia).

The announcement follows the recent publication(1) of data indicating that the compound is as effective as Relenza(R) and Tamiflu(R) against various influenza strains. Significantly this efficacy is achieved with a single dose, as opposed to a treatment over five days for the established drugs.

A 20 mg dose of CS-8958 is inhaled from powder compartments in the TwinCaps(R) inhaler, which is made of just two plastic parts. Hovione believes this is currently the simplest inhaler being tested in clinical trials and once approved, will be the simplest in the market and have the lowest cost of goods. TwinCaps(R) has no moving parts to deaggregate the dose of powder and only requires a low inspiratory airflow to achieve optimal delivery to the lung. This means that children and the elderly will find it easier to inhale the full dose.

The design challenge for Hovione was to make TwinCaps(R) extremely simple to use, as in the case of a pandemic requiring immediate treatment of large populations, there is an obvious advantage for simple operation. The TwinCaps(R) DPI (to be manufactured in Japan and Europe) is a two-piece unit comprising body and shuttle components. The shuttle has two pre-filled dose chambers, left and right. I
'/>"/>

SOURCE Hovione
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDoses Electronic Dry Powder Inhaler
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
7. Phase III Trial Finds Pharmaxis Bronchitol Effective
8. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
9. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... OAKS, Calif., July 10, 2014   Ceres, Inc ... and seed company, announced today financial results for the ... update on its business. Ceres reported that ... in product performance this growing season in Brazil, which ... affected the company,s sorghum evaluation areas for part of ...
(Date:7/10/2014)... PNAS (Proceedings of the National Academy of Sciences) ... deprivation have a significant effect on our metabolism. The ... time of day to test for diseases such as ... , Researchers from the University of Surrey and The ... sleep deprivation, body clock disruption and metabolism, and discovered ...
(Date:7/10/2014)... and spiders can sit upside down forever. Nanophysics makes sure ... in an article just published in Physical Review E ... Geckos and spiders that seem to be able to sit ... worldwide for many years. We will soon be able to ... the gecko,s foot. But the fact is, sooner or later ...
(Date:1/15/2014)... a club sandwich at the nanoscale, National Institute ... in crafting a uniform, multi-walled carbon-nanotube-based coating that ... in upholstered furniture and other soft furnishings. , ... reduced 35 percent compared with untreated foam. As ...
Breaking Biology Technology:Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2
... Case Western Reserve University Biomedical Engineering Department has set ... and the aged, the critically ill and traumatically injured. ... as it celebrates its 40th anniversary, Thursday, Oct. 22. ... in the nation to offer graduate and undergraduate biomedical ...
... International is pleased to announce that the United States ... 7,604,929 to Celsis In Vitro Technologies (Celsis IVT). ... creates its unique LiverPool(TM) products for drug discovery research. ... to create large lots with targeted activity levels. The ...
... The Colorado Center for Reproductive Medicine (CCRM) announced today a ... vitro fertilization (IVF) with comprehensive chromosome screening (CCS), an ongoing ... about 30% worldwide. , In May of 2007, CCRM ... of chromosomes in a few cells removed from the embryo ...
Cached Biology Technology:40 Years on the Leading Edge: Case Western Reserve University's Biomedical Engineering Department Commemorates Achievement, Looks to Future 2Celsis IVT Granted U.S. Patent for LiverPool(TM) Hepatocytes 2Colorado Center for Reproductive Medicine Improves Pregnancy and Implantation Rates Using Comprehensive Chromosomal Screening of IVF Embryos 2Colorado Center for Reproductive Medicine Improves Pregnancy and Implantation Rates Using Comprehensive Chromosomal Screening of IVF Embryos 3
(Date:7/10/2014)... , June 27, 2014  Pomerantz LLP has ... Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain ... United States District Court, Middle District of ... behalf of a class consisting of all persons ... securities between December 17, 2013 and May 22, ...
(Date:7/10/2014)... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on the growing ... was interviewed on July 1 st on the Downtown ... Mr. Pereira discusses the company,s next generation smart wallet with ... Wocket™ aims to replace a traditional wallet with a new ... tells Gino he has never heard of the Wocket and ...
(Date:7/10/2014)... July 8, 2014 Fingerprint ... new design win (DW). An Asian OEM has selected FPC1021 ... production start in August 2014.   FPC is ... which has a planned date for start of mass production ... order of SEK 5M, for delivery in the first half ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... injuries have difficulty developing story-telling skills even though other ... with other children as they mature, research at the ... there may be limitations to the remarkable flexibility for ... zlem Ece Demir, a researcher at the University of ...
... migration to and from Mexico complete an even more ... from the University of Guelph reveals that some North American ... east over the Appalachians and settle along the eastern seaboard. ... north directly from the Gulf coast. The study ...
... our hearts and blood vessels. Conventional treatment attempts to ... the blood plasma. The opposite approach, which involves increasing ... has proven unpopular among patients up to now. The ... has an unpleasant but harmless side-effect: the drug ...
Cached Biology News:Children with brain injuries have problems with story-telling 2U of G research reveals how monarchs fly away home 2Preventing heart problems while keeping a cool head 2Preventing heart problems while keeping a cool head 3
ID clarifier: platform...
... Engine Tetrad 2 thermal cycler accommodates ... (sample-holder, heat-pump assemblies), which hold different ... Pentium-class computer drives an advanced graphical ... and lid temperatures. Peltier heat pumps, ...
4',6-Diamidino-2-phenylindole, dihydrochloride (DAPI)...
... the drug discovery process in mind. Due ... Safire is the ideal instrument to bridge ... throughput screening. Safire is a fully modular ... range of high speed detection techniques. In ...
Biology Products: